Blackstone closes largest ever private funding investment round at $6.3bn

Group 1 - Blackstone has successfully raised $6.3 billion for its life sciences investment strategy, marking the largest private fund ever raised in this sector [1] - The BXLS platform has allocated nearly $2 billion to various life sciences companies over the past year, including a significant $700 million investment in MSD for the development of an antibody-drug conjugate [2] - The platform also invested $400 million in Teva Pharmaceutical's duvakitug program and partnered with Johnson & Johnson for future clinical trials of an AML drug [3] Group 2 - Blackstone Life Sciences has achieved 34 approvals for innovative medicines and devices, including notable therapies like Alnylam Pharmaceuticals' ATTR therapy and AbbVie & J&J's BTK inhibitor [4] - The recent funding round reflects Blackstone's strong commitment to the life sciences sector, which remains a core focus area for the firm [5] - The life sciences sector is currently facing challenges due to rising interest rates and economic uncertainty, but there are signs of recovery in pharma funding, with a 70.6% increase in venture capital investments in Q4 2025 compared to Q3 [6][7] Group 3 - There is a notable shift in investor activity towards cell and gene therapy, with increased interest in Series B-stage candidates as investors become more selective [8]